Skip to main content

Table 3 Conditional and post-test probability performance of the IHC based prediction model in the training and validation cohort

From: Prediction of response to pemetrexed in non-small-cell lung cancer with immunohistochemical phenotyping based on gene expression profiles

 

Training cohort

Validation cohort Responder: PR

Validation cohort Responder: PR + SD

Prevalence (responder)

63.3 (49.9–75.4)

26.1 (10.2–48.4)

56.5 (34.5–76.8)

Sensitivity

86.8 (71.9–95.6)

33.3 (4.3–77.7)

15.4 (1.9–45.5)

Specificity

63.6 (40.7–82.8)

82.4 (56.6–96-2)

70.0 (34.6–93.3)

LR+ (weighted by prevalence)

2.39 (1.36–4.21)

1.89 (0.41–8.71)

0.51 (0.10–2.51)

LR- (weighted by prevalence)

0.21 (0.09–0.50)

0.81 (0.44–1.49)

1.21 (0.76–1.93)

PPV

80.5 (70.1–87.9)

40.0 (12.6–75.5)

40.0 (12.0–76.5)

NPV

73.7 (53.8–87.1)

77.8 (65.6–86.5)

38.9 (28.5–50.4)

  1. Data are expressed as percentages, except LR+ and LR- (odds), with 95% confidence intervals. Abbreviations: LR+ positive likelihood ratio, LR- negative likelihood ratio, PPV positive predictive value, NPV negative predictive value